The gamble between oncolytic virus therapy and IFN

Li, Qingbo; Tan, Fengxian; Wang, Yuanyuan; Liu, Xiaohui; Kong, Xianbin; Jing-yan, Meng; Yang, Long; Cen, Shan

doi:10.3389/fimmu.2022.971674

Cited by 17 publications

(11 citation statements)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After both oncolytic viruses’ treatment, levels of IFN-γ were upregulated ( Figures 3B, C ). This upregulation is a sign of antiviral responses in the TME ( 29 ). Then, both oncolytic viruses mainly presented a downregulation of proteins involved in tumoral cell progression and survival, such as interleukin-8 (IL-8), C-C motif chemokine ligand 20 (CCL20), and galectin-1 (Gal-1) ( Figures 3B, C ).…”

Section: Resultsmentioning

confidence: 99%

Patient-derived tumoroids and proteomic signatures: tools for early drug discovery

Lê,

Deforges,

Cutolo

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Onco-virotherapy is an emergent treatment for cancer based on viral vectors. The therapeutic activity is based on two different mechanisms including tumor-specific oncolysis and immunostimulatory properties. In this study, we evaluated onco-virotherapy in vitro responses on immunocompetent non-small cell lung cancer (NSCLC) patient-derived tumoroids (PDTs) and healthy organoids. PDTs are accurate tools to predict patient’s clinical responses at the in vitro stage. We showed that onco-virotherapy could exert specific antitumoral effects by producing a higher number of viral particles in PDTs than in healthy organoids. In the present work, we used multiplex protein screening, based on proximity extension assay to highlight different response profiles. Our results pointed to the increase of proteins implied in T cell activation, such as IFN-γ following onco-virotherapy treatment. Based on our observation, oncolytic viruses-based therapy responders are dependent on several factors: a high PD-L1 expression, which is a biomarker of greater immune response under immunotherapies, and the number of viral particles present in tumor tissue, which is dependent to the metabolic state of tumoral cells. Herein, we highlight the use of PDTs as an alternative in vitro model to assess patient-specific responses to onco-virotherapy at the early stage of the preclinical phases.

show abstract

Section: Resultsmentioning

confidence: 99%

Patient-derived tumoroids and proteomic signatures: tools for early drug discovery

Lê,

Deforges,

Cutolo

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The STAT heterodimer then proceeds to the nucleus to bind with IRF9 and consequently form a transcriptional activator known as an IFN-stimulated gene factor (ISGF). ISGF integrates with a transcriptional enhancer known as an IFN-stimulated response element (ISRE), which holds the role of the final cascade activator of IFN-stimulated genes (ISGs) [ 50 , 51 ].…”

Section: Innate Immune Response To Epstein–barr Virusmentioning

confidence: 99%

Deciphering the Role of Epstein–Barr Virus Latent Membrane Protein 1 in Immune Modulation: A Multifaced Signalling Perspective

Šimičić,

Batović,

Stojanović Marković

et al. 2024

Viruses

View full text Add to dashboard Cite

The disruption of antiviral sensors and the evasion of immune defences by various tactics are hallmarks of EBV infection. One of the EBV latent gene products, LMP1, was shown to induce the activation of signalling pathways, such as NF-κB, MAPK (JNK, ERK1/2, p38), JAK/STAT and PI3K/Akt, via three subdomains of its C-terminal domain, regulating the expression of several cytokines responsible for modulation of the immune response and therefore promoting viral persistence. The aim of this review is to summarise the current knowledge on the EBV-mediated induction of immunomodulatory molecules by the activation of signal transduction pathways with a particular focus on LMP1-mediated mechanisms. A more detailed understanding of the cytokine biology molecular landscape in EBV infections could contribute to the more complete understanding of diseases associated with this virus.

show abstract

“…When a viral infection is encountered, PRR performs its vital function of antigen recognition and immune initiation at this moment. Immune signals are transmitted through a variety of different pathways, leading to the synthesis and release of a number of inflammatory factors, such as type I interferon (IFN-I) (Lin and Zheng, 2019;Zhu et al, 2022a;Li et al, 2022e;Gong et al, 2022).…”

Section: Direct Invasion and Lysis Of Cancer Cellsmentioning

confidence: 99%

HSV: The scout and assault for digestive system tumors

Li²,

Ren³

et al. 2023

Front. Mol. Biosci.

Self Cite

View full text Add to dashboard Cite

More than 25% of all malignant tumors are digestive system tumors (DSTs), which mostly include esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, gallbladder cancer and cholangiocarcinoma, and colorectal cancer. DSTs have emerged as one of the prominent reasons of morbidity and death in many nations and areas around the world, posing a serious threat to human life and health. General treatments such as radiotherapy, chemotherapy, and surgical resection can poorly cure the patients and have a bad prognosis. A type of immunotherapy known as oncolytic virus therapy, have recently shown extraordinary anti-tumor effectiveness. One of the viruses that has been the subject of the greatest research in this field, the herpes simplex virus (HSV), has shown excellent potential in DSTs. With a discussion of HSV-1 based on recent studies, we outline the therapeutic effects of HSV on a number of DSTs in this review. Additionally, the critical function of HSV in the detection of cancers is discussed, and some HSV future possibilities are shown.

show abstract

The gamble between oncolytic virus therapy and IFN

Cited by 17 publications

References 174 publications

Patient-derived tumoroids and proteomic signatures: tools for early drug discovery

Patient-derived tumoroids and proteomic signatures: tools for early drug discovery

Deciphering the Role of Epstein–Barr Virus Latent Membrane Protein 1 in Immune Modulation: A Multifaced Signalling Perspective

HSV: The scout and assault for digestive system tumors

Contact Info

Product

Resources

About